Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871

CLINICAL CANCER RESEARCH

Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,796

erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells

Fiore, P. P. D., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., & Aaronson, S. A. (1987) · Science · doi:10.1126/science.2885917 · Cited by 1,011

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

Wakeling, A. E., Guy, S. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Barker, A. J., & Gibson, K. H. (2002) · PubMed · doi:10.7270/q2pc374f · Cited by 925

The Epidermal Growth Factor Receptor and Its Inhibition in Cancer Therapy

Woodburn, J. R. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00045-x · Cited by 834

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial

Ranson, M., Hammond, L. A., Ferry, D. K., Kris, M. G., Tullo, A. B., Murray, P. I., Miller, V. A., Averbuch, S. D., Ochs, J., Morris, C. Q., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.112 · Cited by 764

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761

Drug binding to human alpha-1-acid glycoprotein in health and disease.

Kremer, J. M., Wilting, J., & Janssen, L. H. M. (1988) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00015-8 · Cited by 584

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

Herbst, R. S., Maddox, A., Rothenberg, M. L., Small, E. J., Rubin, E. H., Baselga, J. M., Rojo, F., Hong, W. K., Swaisland, H., Averbuch, S. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.038 · Cited by 572

Screening candidate anticancer drugs for brain tumor chemotherapy: Pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues

Lv, H., Wang, F., Reddy, M. V. R., Zhou, Q. S., Zhang, X., Reddy, E. P., & Gallo, J. M. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9806-x · Cited by 7

Progression of Central Nervous System Metastases in Advanced Nonsmall Cell Lung Cancer Patients Effectively Treated with First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor

Yu, M., Zhao, Q., Li, Y., Zhang, S., Xu, Y., Gong, Y., Zhu, J., Ding, Z., Wang, J., Peng, F., et al. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2493 · Cited by 7

Komplette Remission multifokaler zerebraler Metastasen bei chemotherapierefraktärem NSCLC durch Monotherapie mit Gefitinib

Müller, F., Riesenberg, H., Hirnle, P., Gehl, H., Düwel, P., & Görner, M. (2011) · Strahlentherapie und Onkologie · doi:10.1007/s00066-011-2260-4 · Cited by 6

Crosstalk between alveolar macrophages and alveolar epithelial cells/fibroblasts contributes to the pulmonary toxicity of gefitinib

Du, J., Li, G., Jiang, L., Zhang, X., Xu, Z., Yan, H., Zhou, Z., He, Q., Yang, X., & Luo, P. (2020) · Toxicology Letters · doi:10.1016/j.toxlet.2020.11.011 · Cited by 6

Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation

Liu, J., Xing, L., Meng, X., Yue, J., Meng, X., Xie, P., Li, X., Kong, L., & Yu, J. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s100105 · Cited by 5

Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice

Biali, M. E., Auvity, S., Cisternino, S., Smirnova, M., Hacker, M., Zeitlinger, M., Mairinger, S., Tournier, N., Bauer, M., & Langer, O. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00715 · Cited by 4

Design, conduct, and interpretation of human mass balance studies and strategies for assessing metabolites-in-safety testing (MIST) in drug development

Wong, S. G. W., & Ma, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00004-0 · Cited by 4

A validated high‐performance liquid chromatography–tandem mass spectrometry method for quantification of gefitinib and its main metabolites in xenograft mouse tumor: Application to a pharmacokinetics study

Zhao, C., Zheng, N., Yang, F., Han, S., & Li, P. (2019) · Biomedical Chromatography · doi:10.1002/bmc.4638 · Cited by 4

Exacerbation of gefitinib-induced liver injury by glutathione reduction in mice

Oda, S., Miyazaki, N., Tsuneyama, K., & Yokoi, T. (2020) · The Journal of Toxicological Sciences · doi:10.2131/jts.45.493 · Cited by 3

Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics

Feng, W., Chen, X., Guan, S., Ruan, H., Huang, Y., Zhang, H., Yang, Y., Fang, W., Zhao, H., Zhuang, W., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00791-5 · Cited by 3

Cranberry Ingestion Modulated Drug Transporters and Metabolizing Enzymes: Gefitinib Used as a Probe Substrate in Rats

Yu, C., Tsai, P.-L., Li, P., Hsu, P.-W., Lin, S.-P., Chao, P.-D. L., & Hou, Y. (2022) · Molecules · doi:10.3390/molecules27185772 · Cited by 3

Solid Dispersions of Gefitinib with D-α-Tocopherol Polyethylene Glycol-1000 Succinate and 2-Hydroxypropyl β-Cyclodextrin Complex Improved Their Solubility, Dissolution and Apoptosis against A549 Cells

Kalam, M. A., Alhowyan, A., Alhudaithi, S. S., Khan, M. S., Alshememry, A. K., & Alkholief, M. A. (2023) · Applied Sciences · doi:10.3390/app131910859 · Cited by 3

Toxicology, Safety and Herb–drug Interactions in Cancer Therapy

Zhou, S. (2009) · Springer eBooks · doi:10.1007/978-90-481-3555-4_12 · Cited by 3

Efficacy and safety of antitumor agents plus radiotherapy compared with radiotherapy alone for brain metastases from lung cancer

Lin, H., Luo, S., Li, L., Zhou, S., Shen, R., Yang, H., Wu, Y., & Xie, X. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1152 · Cited by 3

Design and Synthesis of Gefitinib Derivatives as Potential Drugs fo r Cancer Treatment: Antiproliferative Activity, Molecular Docking, and ADMET Prediction

Ma, X., Shan, M., & Lu, Y. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230810164118 · Cited by 2

Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients

Shenoy, P. V., Baburaj, G., Damerla, R. R., Pai, A., Mailankody, S., Munisamy, M., Mallayasamy, S., Udupa, K., Kolesar, J., & Rao, M. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10299-7 · Cited by 2

[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].

Ding, J., & Zhong, D. (2013) · PubMed · Cited by 2

From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?

Alongi, F., Arcangeli, S., Ramella, S., Giaj‐Levra, N., Borghetti, P., D’Angelillo, R. M., Ricchetti, F., Maddalo, M., Mazzola, R., Trovò, M., et al. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1273111 · Cited by 2

Alterations of Gefitinib Pharmacokinetics by Co-administration of Herbal Medications in Rats

Weon, K.-Y., Kim, M. G., Shin, S., Kim, T. H., Joo, S. H., Ma, E., Jeong, S. W., Yoo, S. D., Youn, Y. S., & Shin, B. S. (2018) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-017-2907-9 · Cited by 2

Clinical Pharmacology in Pediatrics

Tagen, M., & Stewart, C. (2014) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9135-4_31

Targeting the epidermal growth factor receptor (EGFR) pathway for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Zainal, H. (2016) · UCL Discovery (University College London) · Cited by 1

Chemoprevention of Lung Carcinogenesis: Aerosol Administration and Deposition in the Mouse Lung

Zhang, J. (2013) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7gf0rjb

Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib

van Erp, P. E. J., & Hubertha, P. (2009)

Gefitinib: Re-Emerging from the Shadows

Martin, P., Owen, S. P., & Leighl, N. B. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.42

Comparison of Gefitinib Versus VMP in the Combination with Radiotherapy for Multiple Brain Metastases from Non-small Cell Lung Cancer

Liu, F. W. N., HaoLiMian, Y., Yu, L., & Li, S. C. (2015)

Gefitinib

Meng, J. (2013) · Handbook of Metabolic Pathways of Xenobiotics · doi:10.1002/9781118541203.xen545

Gefitinib

Beljanski, V. (2007) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.63724-9

HB-EGF and zinc activate EGFR to induce reactive neural stem cells in the mouse hippocampus after seizuresPreprint

Pastor-Alonso, O., Durá, I., Bernardo-Castro, S., Varea, E., Muro‐García, T., Martín‐Suárez, S., Encinas, J. M., & Pineda, J. R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.02.514820

Radioisotope-labeled tyrosine kinase inhibitors in the diagnosis and treatment of lung cancer

Zahid, M., Wang, H., Li, Y., & Zhang, J. (2025) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-025-10295-9

Etude du métabolisme d'inhibiteurs de tyrosine kinases, caractérisation de nouveaux métabolites réactifs du pazopanib et du sunitinib par une approche de catalyse biomimétique et implication potentielle dans leurs effets indésirables

Paludetto, M. (2019) · doi:10.70675/3b5e9161zd7dez4784zbe34z76905dcba389

BindingDB Entry 50047031: Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents.

BindingDB (2017) · UC San Diego · doi:10.7270/q2tm7d0w

Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog

McKillop, D., Partridge, E. A., Hutchison, M., Rhead, S., Parry, A. C., Bardsley, J., Woodman, H. M., & Swaisland, H. (2004) · Xenobiotica · doi:10.1080/00498250400009189 · Cited by 46

In vitrometabolism of gefitinib in human liver microsomes

McKillop, D., McCormick, A., Miles, G. S., Phillips, P. J., Pickup, K., Bushby, N., & Hutchison, M. (2004) · Xenobiotica · doi:10.1080/02772240400015222 · Cited by 61

Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor

Scheers, E. M., Borgmans, C., Keung, C., Bohets, H., Wynant, I., Poggesi, I., Cuyckens, F., Leclercq, L., & Mamidi, R. N. V. S. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1821123 · Cited by 12

Comprehensive identification, fragmentation pattern, and metabolic pathways of gefitinib metabolites via UHPLC-Q-TOF-MS/MS: in vivo study of rat plasma, urine, bile, and faeces

Gao, X., Zhang, Y., Feng, T., Cao, L., Wu, W., & Qin, K. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1859642 · Cited by 8

Cytochrome P450-dependent metabolism of gefitinib

McKillop, D., McCormick, A., Millar, A., Miles, G. S., Phillips, P. J., & Hutchison, M. (2005) · Xenobiotica · doi:10.1080/00498250400026464 · Cited by 138